Drug Trial Radar · NCT01136551
Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A
Last checked: Nov 20, 2026Latest source record: Jun 3, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
8
Planned (sponsor's estimate)
Start
Sep 2010
Primary completion
Jan 2011
Study completion Apr 2011
Sponsor
- Lead sponsor
- Hadassah Medical OrganizationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hebrew University of Jerusalem
- First posted
- Jun 3, 2010
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to develop oral controlled release formulation of Huperzine A that will provide optimal pharmacokinetic profile of the drug enhancing safety and compliance, as possible cure to neurodegenerative disorders.
Conditions
- Healthy
- Bioavailability
Interventions
Huperzine ADrug
Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic parameters of Huperzine A different formulationsTime frame: Blood samples will be taken for 36 hours after Huperzine A administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hadassah University Hospital
Jerusalem, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.